Search Results

NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that the University of Michigan will begin the pilot phase of its clinical trial of UroShield this week.

NanoVibronix, Inc., a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave Portable Ultrasonic Therapeutic Devices, issued a letter to its stockholders from its Chief Executive Officer, Brian Murphy, providing a review of the first quarter of 2024 and recent business developments.

NanoVibronix, Inc. (Nasdaq:NAOV) (“NanoVibronix” or the “Company”), a medical device company that produces the UroShieldâ, PainShieldâ and WoundShieldâ Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 9:30 AM (Pacific Time).

NanoVibronix, Inc., a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave Portable Ultrasonic Therapeutic Devices, announced that it has entered into a distribution agreement with CB Medical, LLC for the sale and distribution of the Company’s UroShield.

NanoVibronix, Inc., a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave Portable Ultrasonic Therapeutic Devices, announced it has entered into an agreement with Veranex, Inc. to assist with the development of the company’s next generation UroShield and PainShield products.

NanoVibronix, Inc. (NASDAQ: NAOV) today announced that it has entered into a non-binding letter of intent (the “LOI”) with APOGEPHA Arzneimittel GmbH (“APOGEPHA”) in which both parties will analyze the potential for APOGEPHA to distribute NanoVibronix’s premiere UroShield product in Germany and other European markets.

NanoVibronix, Inc. today announced it has signed a Research Agreement with the Regents of the University of Michigan for a Randomized Control Trial (“RCT”) study of UroShield.